Developer docs
API playgroundTry for free, no card

Search company profiles

GeoVax

Full company profile

uuid0002pkj

Namestring
GeoVax
Legal namestring
GeoVax Labs, Inc.
Websiteurl
geovax.com
Company typeenum
Public
Founded yearint
2006
Descriptiontext

GeoVax Labs, Inc. (NASDAQ: GOVX) is a clinical-stage biotechnology company headquartered in Smyrna, Georgia (Atlanta metro) that develops vaccines and immunotherapies for high-consequence infectious diseases and solid tumor cancers. The company operates two core technology platforms: a Modified Vaccinia Ankara (MVA) vaccine platform licensed from the U.S. NIH that generates virus-like particles in vivo to elicit both humoral and cellular immune responses, and a Gene-Directed Enzyme Prodrug Therapy (GDEPT) platform acquired from PNP Therapeutics and supplemented with combination-therapy IP licensed from Emory University. Lead clinical assets include GEO-MVA (a mpox/smallpox vaccine advancing to Phase 3 under EMA scientific advice with a planned Q4 2026 initiation), GEO-CM04S1 (a multi-antigen COVID-19 vaccine for immunocompromised patients in a BARDA-funded Phase 2b), and Gedeptin (a replication-deficient adenovirus-based gene therapy for solid tumors, with FDA Orphan Drug designation in head and neck cancer and a planned Phase 2 combination trial with immune checkpoint inhibitors in H2 2027).

The company is pre-revenue and monetizes primarily through non-dilutive government funding (BARDA Project NextGen award of up to $45M direct funding and up to $388M total program value with clinical research organization partner Allucent), periodic equity issuances, and future expectations of government procurement contracts for orthopox preparedness and biodefense, supplemented by potential licensing royalties from oncology assets. Manufacturing capability is being transitioned to a scalable, continuous AGE1.CR.pIX avian cell line licensed from ProBioGen AG, replacing legacy chicken embryonic fibroblast processes. Primary future buyers are federal health agencies (BARDA, CDC, Strategic National Stockpile) for vaccines and academic cancer centers for Gedeptin adoption. Customer concentration in future revenue is therefore structurally High.

Short descriptiontext

GeoVax Labs is a clinical-stage biotechnology company developing MVA-vectored vaccines for mpox, smallpox, COVID-19, and hemorrhagic fevers, plus a GDEPT gene therapy (Gedeptin) for solid tumors, targeting U.S. government biodefense procurement and oncology indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSmyrna, United States
HQ citystring
Smyrna
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage vaccines, infectious disease vaccines, oncology immunotherapies, mpox smallpox vaccine, biodefense biologics
Industry4 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biotechnology Vaccines and Cancer Immunotherapies
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Vaccine Product Sales
TypeOne Time License
Description

Revenue expected from commercial sales of GEO-MVA vaccine for mpox and smallpox upon regulatory approval, targeting government procurement and public health markets.

geovax.com
2Gedeptin Oncology Licensing
TypeLicensing Royalties
Description

Potential licensing revenue from Gedeptin technology for solid tumor treatment, including combination therapies with immune checkpoint inhibitors.

geovax.com
3Government Contracts & BARDA Funding
TypeManaged Services
Description

Funding from BARDA (up to $45 million) and other government agencies for clinical development of COVID-19 and other vaccines.

prnewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1GEO-MVA
Description

Modified Vaccinia Ankara (MVA) vaccine candidate targeting mpox and smallpox

geovax.com
+2 more records
Core offering1 text field

GeoVax Labs, Inc. is a clinical-stage biotechnology company that develops vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers. Its primary products are the GEO-MVA vaccine for mpox and smallpox (targeting Phase 3 in Q4 2026), the Gedeptin® gene-directed enzyme prodrug therapy for head and neck cancer (Phase 2 planned H2 2027 in combination with immune checkpoint inhibitors), and the GEO-CM04S1 next-generation COVID-19 vaccine for immunocompromised patients (BARDA-funded Phase 2b). All candidates are built on the company's proprietary MVA vector platform or its GDEPT oncology platform and are intended for sale or licensing to government health agencies, biodefense programs, and cancer-treatment institutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 3 trial expected to enroll approximately 500 participants evaluating neutralizing antibody responses vs approved MVA vaccine
+2 more records
Product overview1 text field

GeoVax Labs, Inc. is a clinical-stage biotechnology company utilizing two core technology platforms to develop a portfolio of vaccines and immunotherapies. The Modified Vaccinia Ankara (MVA) platform is used for creating preventive vaccines against infectious diseases, while the Gene-Directed Enzyme Prodrug Therapy (GDEPT) platform powers its oncology programs. The product portfolio includes: GEO-MVA (the near-term priority mpox and smallpox vaccine advancing toward Phase 3), GEO-CM04S1 (a next-generation COVID-19 vaccine for immunocompromised patients), hemorrhagic fever virus vaccines (Ebola Zaire, Ebola Sudan, and Marburg), and Gedeptin® (a gene therapy for solid tumors, initially focused on head and neck cancers, now advancing to Phase 2 in combination with immune checkpoint inhibitors).

Product and service5 records
1GEO-MVA
CategoryVaccine Product Candidate (Infectious Disease)
Description

GEO-MVA is a Modified Vaccinia Ankara (MVA)-based vaccine candidate for mpox, smallpox, and other orthopoxviruses, intended to address global MVA vaccine supply constraints and support civilian public health and biodefense stockpiles.

2Gedeptin®
CategoryOncology Gene Therapy Product Candidate
Description

Gedeptin® is a novel patented gene therapy for solid tumors using Gene-Directed Enzyme Prodrug Therapy (GDEPT), in which a replication-deficient adenovirus vector delivers a nonhuman gene expressing an enzyme that converts inactive prodrug (fludarabine phosphate) into active antitumor compound in situ; it holds FDA Orphan Drug designation for head and neck cancers.

3GEO-CM04S1
CategoryCOVID-19 Vaccine Candidate (Infectious Disease)
Description

GEO-CM04S1 is a next-generation MVA-vectored, multi-antigen COVID-19 vaccine candidate designed for immunocompromised patients, supported by BARDA Project NextGen funding with a head-to-head Phase 2b design vs. an FDA-approved mRNA vaccine.

4Hemorrhagic Fever Virus Vaccines
CategoryVaccine Product Candidates (Infectious Disease)
Description

Vaccine candidates targeting Ebola Zaire, Ebola Sudan, and Marburg viruses developed using the MVA vaccine platform, representing a strategic extension into global health security and biodefense against high-mortality hemorrhagic fevers; preclinical data have demonstrated protective immune responses and survival benefits in animal studies, though programs are not currently under active development.

5Gedeptin + Immune Checkpoint Inhibitor Combination
CategoryOncology Combination Therapy Product Candidate
Description

Gedeptin + Immune Checkpoint Inhibitor (ICI) Combination is an exclusive worldwide in-licensed program from Emory University that combines Gedeptin gene therapy with ICI therapy to convert immunologically cold tumors into more immune-responsive tumors in head and neck squamous cell carcinoma.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-09-01
Description

In September 2021, GeoVax entered into an assignment and license agreement with PNP Therapeutics granting exclusive worldwide rights to develop and commercialize Gedeptin for all human diseases and conditions including solid tumors. The Gedeptin technology was developed with funding support from the National Cancer Institute (NCI), part of the NIH.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

GeoVax entered into an exclusive worldwide license agreement with Emory University for intellectual property covering the use of Gedeptin in combination with Immune Checkpoint Inhibitors. The licensed technology supports the combination of GDEPT-based tumor debulking with checkpoint blockade.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Clinical research organization supporting the BARDA-funded Phase 2b clinical study of GEO-CM04S1 next-generation COVID-19 vaccine candidate.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

GeoVax licensed the AGE1.CR.pIX continuous avian cell line system from ProBioGen AG for manufacturing MVA-based vaccines. This advanced manufacturing process intends to significantly increase yield and volume capacity while reducing manufacturing costs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

GeoVax announced a research program to evaluate needle-free, self-administered GEO-MVA vaccine using Vaxxas microarray patch technology for potential distribution advantages.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Danish biotech and the most direct competitor in the MVA/mpox/smallpox vaccine space with FDA-approved JYNNEOS (MVA-BN). Competes head-to-head with GeoVax's GEO-MVA in government stockpiling, public health preparedness, and commercial orthopoxvirus vaccine markets.

TypeDirect peer
Description

U.S. biodefense-focused company with ACAM2000 smallpox vaccine and a broader portfolio of medical countermeasures. Directly comparable as a competing orthopoxvirus vaccine supplier and biodefense procurement contractor for government stockpiles.

TypeDirect peer
Description

Specialty biodefense company with FDA-approved TPOXX (tecovirimat) smallpox antiviral and government stockpiling contracts. Comparable as a small-cap public biodefense-focused biotech competing for Strategic National Stockpile budgets alongside GeoVax.

TypeDirect peer
Description

Clinical-stage biotech developing TNX-801, a horsepox-based vaccine for smallpox and mpox, with similar regulatory pathway and target market to GeoVax's GEO-MVA. Comparable as a small-cap public peer in the orthopoxvirus vaccine space.

TypeDirect peer
Description

Clinical-stage biotech developing antiviral therapies including smallpox and other infectious disease countermeasures, with similar focus on government biodefense procurement and BARDA-funded development. Comparable as a small-cap infectious disease biotech targeting similar stockpiling customers.

TypeDirect peer
Description

Vaccitech was a UK-based MVA platform company that developed the Oxford/AstraZeneca COVID-19 vaccine using a related simian adenovirus/MVA prime-boost approach. Now Barinthus Biotherapeutics, it represents the most direct MVA-platform peer with shared vector technology heritage and comparable infectious disease focus.

TypeBroad incumbent
Description

Larger clinical/commercial-stage vaccine company with Nuvaxovid (protein subunit COVID-19 vaccine) and a broader pipeline including influenza vaccines. Comparable as a competing COVID-19 vaccine developer for immunocompromised populations and a public vaccine platform peer, though at a substantially larger scale.

TypeBroad incumbent
Description

Leading mRNA vaccine company with Spikevax (COVID-19) and mpox vaccine candidate (mRNA-1769) in development. Comparable as a competitor in both COVID-19 immunocompromised vaccination and mpox vaccine development, though at vastly greater scale and resources.

TypeEmerging player
Description

Clinical-stage oncolytic immunotherapy company developing RP1, RP2, and RP3 for solid tumors including in combination with checkpoint inhibitors. Comparable as a small public clinical-stage biotech pursuing intratumoral/immunotherapy combinations for solid tumors, overlapping with GeoVax's Gedeptin strategy.

TypeOthers
Description

Medical device company developing needle-free injection systems for vaccine delivery, comparable to GeoVax's Vaxxas microarray patch partnership. Relevant as a complementary/enabling technology partner in the vaccine delivery space rather than a direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GeoVax

Biotechnology Vaccines and Cancer Immunotherapiesgeovax.com

GeoVax Labs is a clinical-stage biotechnology company developing MVA-vectored vaccines for mpox, smallpox, COVID-19, and hemorrhagic fevers, plus a GDEPT gene therapy (Gedeptin) for solid tumors, targeting U.S. government biodefense procurement and oncology indications.

What GeoVax does

GeoVax Labs, Inc. (NASDAQ: GOVX) is a clinical-stage biotechnology company headquartered in Smyrna, Georgia (Atlanta metro) that develops vaccines and immunotherapies for high-consequence infectious diseases and solid tumor cancers. The company operates two core technology platforms: a Modified Vaccinia Ankara (MVA) vaccine platform licensed from the U.S. NIH that generates virus-like particles in vivo to elicit both humoral and cellular immune responses, and a Gene-Directed Enzyme Prodrug Therapy (GDEPT) platform acquired from PNP Therapeutics and supplemented with combination-therapy IP licensed from Emory University. Lead clinical assets include GEO-MVA (a mpox/smallpox vaccine advancing to Phase 3 under EMA scientific advice with a planned Q4 2026 initiation), GEO-CM04S1 (a multi-antigen COVID-19 vaccine for immunocompromised patients in a BARDA-funded Phase 2b), and Gedeptin (a replication-deficient adenovirus-based gene therapy for solid tumors, with FDA Orphan Drug designation in head and neck cancer and a planned Phase 2 combination trial with immune checkpoint inhibitors in H2 2027).

The company is pre-revenue and monetizes primarily through non-dilutive government funding (BARDA Project NextGen award of up to $45M direct funding and up to $388M total program value with clinical research organization partner Allucent), periodic equity issuances, and future expectations of government procurement contracts for orthopox preparedness and biodefense, supplemented by potential licensing royalties from oncology assets. Manufacturing capability is being transitioned to a scalable, continuous AGE1.CR.pIX avian cell line licensed from ProBioGen AG, replacing legacy chicken embryonic fibroblast processes. Primary future buyers are federal health agencies (BARDA, CDC, Strategic National Stockpile) for vaccines and academic cancer centers for Gedeptin adoption. Customer concentration in future revenue is therefore structurally High.

GeoVax firmographics

Firmographics
Name
GeoVax
Legal name
GeoVax Labs, Inc.
Website
https://geovax.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
GeoVax Labs is a clinical-stage biotechnology company developing MVA-vectored vaccines for mpox, smallpox, COVID-19, and hemorrhagic fevers, plus a GDEPT gene therapy (Gedeptin) for solid tumors, targeting U.S. government biodefense procurement and oncology indications.
Ownership category
akta.pro rank

GeoVax industry classification

Industry
Product category
Biotechnology Vaccines and Cancer Immunotherapies
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)

Keywords

  • Clinical-stage vaccines
  • Infectious disease vaccines
  • Oncology immunotherapies
  • Mpox smallpox vaccine
  • Biodefense biologics

Where GeoVax is headquartered

Location

Headquarters

HQ city
Smyrna
HQ country
United States
HQ region
North America

Offices1 record

Markets served

GeoVax business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Vaccine Product Sales: Revenue expected from commercial sales of GEO-MVA vaccine for mpox and smallpox upon regulatory approval, targeting government procurement and public health markets.
  2. Gedeptin Oncology Licensing: Potential licensing revenue from Gedeptin technology for solid tumor treatment, including combination therapies with immune checkpoint inhibitors.
  3. Government Contracts & BARDA Funding: Funding from BARDA (up to $45 million) and other government agencies for clinical development of COVID-19 and other vaccines.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

GeoVax product offering

Product offering

Core offering

GeoVax Labs, Inc. is a clinical-stage biotechnology company that develops vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers. Its primary products are the GEO-MVA vaccine for mpox and smallpox (targeting Phase 3 in Q4 2026), the Gedeptin® gene-directed enzyme prodrug therapy for head and neck cancer (Phase 2 planned H2 2027 in combination with immune checkpoint inhibitors), and the GEO-CM04S1 next-generation COVID-19 vaccine for immunocompromised patients (BARDA-funded Phase 2b). All candidates are built on the company's proprietary MVA vector platform or its GDEPT oncology platform and are intended for sale or licensing to government health agencies, biodefense programs, and cancer-treatment institutions.

Product overview

GeoVax Labs, Inc. is a clinical-stage biotechnology company utilizing two core technology platforms to develop a portfolio of vaccines and immunotherapies. The Modified Vaccinia Ankara (MVA) platform is used for creating preventive vaccines against infectious diseases, while the Gene-Directed Enzyme Prodrug Therapy (GDEPT) platform powers its oncology programs. The product portfolio includes: GEO-MVA (the near-term priority mpox and smallpox vaccine advancing toward Phase 3), GEO-CM04S1 (a next-generation COVID-19 vaccine for immunocompromised patients), hemorrhagic fever virus vaccines (Ebola Zaire, Ebola Sudan, and Marburg), and Gedeptin® (a gene therapy for solid tumors, initially focused on head and neck cancers, now advancing to Phase 2 in combination with immune checkpoint inhibitors).

Differentiator

Problem solved

Functional benefit

Brands

  • GEO-MVA: Modified Vaccinia Ankara (MVA) vaccine candidate targeting mpox and smallpox
  • Gedeptin
  • GEO-CM04S1

Products and services

  • GEO-MVA GEO-MVA is a Modified Vaccinia Ankara (MVA)-based vaccine candidate for mpox, smallpox, and other orthopoxviruses, intended to address global MVA vaccine supply constraints and support civilian public health and biodefense stockpiles.
  • Gedeptin® Gedeptin® is a novel patented gene therapy for solid tumors using Gene-Directed Enzyme Prodrug Therapy (GDEPT), in which a replication-deficient adenovirus vector delivers a nonhuman gene expressing an enzyme that converts inactive prodrug (fludarabine phosphate) into active antitumor compound in situ; it holds FDA Orphan Drug designation for head and neck cancers.
  • GEO-CM04S1 GEO-CM04S1 is a next-generation MVA-vectored, multi-antigen COVID-19 vaccine candidate designed for immunocompromised patients, supported by BARDA Project NextGen funding with a head-to-head Phase 2b design vs. an FDA-approved mRNA vaccine.
  • Hemorrhagic Fever Virus Vaccines Vaccine candidates targeting Ebola Zaire, Ebola Sudan, and Marburg viruses developed using the MVA vaccine platform, representing a strategic extension into global health security and biodefense against high-mortality hemorrhagic fevers; preclinical data have demonstrated protective immune responses and survival benefits in animal studies, though programs are not currently under active development.
  • Gedeptin + Immune Checkpoint Inhibitor Combination Gedeptin + Immune Checkpoint Inhibitor (ICI) Combination is an exclusive worldwide in-licensed program from Emory University that combines Gedeptin gene therapy with ICI therapy to convert immunologically cold tumors into more immune-responsive tumors in head and neck squamous cell carcinoma.

Quantifiable outcome

  • Phase 3 trial expected to enroll approximately 500 participants evaluating neutralizing antibody responses vs approved MVA vaccine
  • +2 more outcomes

Companies that use GeoVax

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

GeoVax technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

GeoVax partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, major and minor.

  • PNP Therapeutics, Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 September 2021In September 2021, GeoVax entered into an assignment and license agreement with PNP Therapeutics granting exclusive worldwide rights to develop and commercialize Gedeptin for all human diseases and conditions including solid tumors. The Gedeptin technology was developed with funding support from the National Cancer Institute (NCI), part of the NIH.
  • Emory UniversitycoreOEM/ Whitelabel/ Licensing PartnerGeoVax entered into an exclusive worldwide license agreement with Emory University for intellectual property covering the use of Gedeptin in combination with Immune Checkpoint Inhibitors. The licensed technology supports the combination of GDEPT-based tumor debulking with checkpoint blockade.
  • AllucentmajorStrategic or Co-development PartnerClinical research organization supporting the BARDA-funded Phase 2b clinical study of GEO-CM04S1 next-generation COVID-19 vaccine candidate.
  • ProBioGen AGcoreOEM/ Whitelabel/ Licensing PartnerGeoVax licensed the AGE1.CR.pIX continuous avian cell line system from ProBioGen AG for manufacturing MVA-based vaccines. This advanced manufacturing process intends to significantly increase yield and volume capacity while reducing manufacturing costs.
  • VaxxasminorStrategic or Co-development PartnerGeoVax announced a research program to evaluate needle-free, self-administered GEO-MVA vaccine using Vaxxas microarray patch technology for potential distribution advantages.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

GeoVax competitors and assessment

Company assessment

Direct peers

  • Bavarian Nordic: Danish biotech and the most direct competitor in the MVA/mpox/smallpox vaccine space with FDA-approved JYNNEOS (MVA-BN). Competes head-to-head with GeoVax's GEO-MVA in government stockpiling, public health preparedness, and commercial orthopoxvirus vaccine markets.
  • Emergent BioSolutions: U.S. biodefense-focused company with ACAM2000 smallpox vaccine and a broader portfolio of medical countermeasures. Directly comparable as a competing orthopoxvirus vaccine supplier and biodefense procurement contractor for government stockpiles.
  • SIGA Technologies: Specialty biodefense company with FDA-approved TPOXX (tecovirimat) smallpox antiviral and government stockpiling contracts. Comparable as a small-cap public biodefense-focused biotech competing for Strategic National Stockpile budgets alongside GeoVax.
  • Tonix Pharmaceuticals: Clinical-stage biotech developing TNX-801, a horsepox-based vaccine for smallpox and mpox, with similar regulatory pathway and target market to GeoVax's GEO-MVA. Comparable as a small-cap public peer in the orthopoxvirus vaccine space.
  • Chimerix: Clinical-stage biotech developing antiviral therapies including smallpox and other infectious disease countermeasures, with similar focus on government biodefense procurement and BARDA-funded development. Comparable as a small-cap infectious disease biotech targeting similar stockpiling customers.
  • Barinthus Biotherapeutics (formerly Vaccitech): Vaccitech was a UK-based MVA platform company that developed the Oxford/AstraZeneca COVID-19 vaccine using a related simian adenovirus/MVA prime-boost approach. Now Barinthus Biotherapeutics, it represents the most direct MVA-platform peer with shared vector technology heritage and comparable infectious disease focus.

Broad incumbents

  • Novavax: Larger clinical/commercial-stage vaccine company with Nuvaxovid (protein subunit COVID-19 vaccine) and a broader pipeline including influenza vaccines. Comparable as a competing COVID-19 vaccine developer for immunocompromised populations and a public vaccine platform peer, though at a substantially larger scale.
  • Moderna: Leading mRNA vaccine company with Spikevax (COVID-19) and mpox vaccine candidate (mRNA-1769) in development. Comparable as a competitor in both COVID-19 immunocompromised vaccination and mpox vaccine development, though at vastly greater scale and resources.

Emerging players

  • Replimune Group: Clinical-stage oncolytic immunotherapy company developing RP1, RP2, and RP3 for solid tumors including in combination with checkpoint inhibitors. Comparable as a small public clinical-stage biotech pursuing intratumoral/immunotherapy combinations for solid tumors, overlapping with GeoVax's Gedeptin strategy.

Others

  • PharmaJet: Medical device company developing needle-free injection systems for vaccine delivery, comparable to GeoVax's Vaxxas microarray patch partnership. Relevant as a complementary/enabling technology partner in the vaccine delivery space rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

GeoVax social profiles

Digital presence

GeoVax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GeoVax leadership team

Management profile

Number of profiles

Profiles21 records

GeoVax funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GeoVax M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeoVax

What does GeoVax do?

GeoVax Labs, Inc. is a clinical-stage biotechnology company that develops vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers. Its primary products are the GEO-MVA vaccine for mpox and smallpox (targeting Phase 3 in Q4 2026), the Gedeptin® gene-directed enzyme prodrug therapy for head and neck cancer (Phase 2 planned H2 2027 in combination with immune checkpoint inhibitors), and the GEO-CM04S1 next-generation COVID-19 vaccine for immunocompromised patients (BARDA-funded Phase 2b). All candidates are built on the company's proprietary MVA vector platform or its GDEPT oncology platform and are intended for sale or licensing to government health agencies, biodefense programs, and cancer-treatment institutions.

Is GeoVax a public or private company?

GeoVax is a public company. It is classified as public and is currently operating.

When was GeoVax founded?

GeoVax was founded in 2006. It employs 11 to 50 people.

Where is GeoVax based?

GeoVax is headquartered in Smyrna, United States, in the North America region.

How does GeoVax make money?

Three revenue lines are on record. Vaccine Product Sales are the primary driver. The others are gedeptin Oncology Licensing and government Contracts & BARDA Funding.

Who are GeoVax's main competitors?

Direct peers on record are Bavarian Nordic, Emergent BioSolutions, SIGA Technologies, Tonix Pharmaceuticals, Chimerix and Barinthus Biotherapeutics (formerly Vaccitech). Broad incumbents are Novavax and Moderna. Replimune Group is listed as an emerging player. PharmaJet is listed as an others.

Does GeoVax have an API?

No public API is recorded for GeoVax.

What industry is GeoVax in?

GeoVax's product category is Biotechnology Vaccines and Cancer Immunotherapies. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAIAEAF, Pandemic Preparedness & Rapid-Response Vaccines. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewGeoVax Labs names Anna Skowron interim CFO as Mark Reynolds resignsGeoVax Labs appointed Anna Skowron as CFO and principal financial officer, effective November 16, 2026, following Mark W. Reynolds' resignation. Skowron serves as a non-employee officer on a fractional basis, with BPC Consulting Ltd. receiving $10,000 monthly and eligible for a performance-based bonus.The future of tradingGeoVax Labs Names Anna Skowron Interim CFOGeoVax Labs appointed Anna Skowron as interim CFO effective November 16, 2026, on a fractional basis. Mark W. Reynolds resigned as CFO and corporate secretary on November 13, 2026, and Chief Medical Officer Kelly T. McKee was terminated immediately on November 17, 2026.American Banking and Market NewsHead-To-Head Review: GeoVax Labs (NASDAQ:GOVX) & PTC Therapeutics (NASDAQ:PTCT)A head-to-head review compares GeoVax Labs and PTC Therapeutics on revenue, earnings, and analyst ratings. PTC Therapeutics has higher revenue and earnings but a lower price-to-earnings ratio, while GeoVax Labs shows higher probable upside. Analysts favor GeoVax Labs on 10 of 15 factors.American Banking and Market NewsGeoVax Labs (GOVX) Expected to Post Earnings on ThursdayGeoVax Labs is expected to report Q3 2026 earnings on November 12th, with analysts projecting a loss of $1.09 per share. The stock opened at $0.14, and analysts have set a consensus target price of $150.00 with a Hold rating.MarketWatchGeoVax Labs Names Tyler O'Brien as Chairman and Interim CEOGeoVax Labs named Tyler O'Brien chairman and interim CEO, succeeding David Dodd, who was terminated for cause on Nov. 5. The termination was unrelated to business operations or financial results, and whether cause existed under the employment agreement remains undetermined by a court or arbitrator.MarketWatchStocks to Watch: Repligen, Hawaiian Electric, GeoVax LabsRepligen issued $1 billion in convertible senior notes due 2031, and its shares fell 20% to $138.99. Hawaiian Electric reported higher profit and 28% revenue growth, pushing its stock up 2.9% to $8.66. GeoVax Labs fired CEO David Dodd for refusing board directives, and its stock dropped 4.3% to 15 cents.